Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate
Open Access
- 18 October 2020
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 10 (20) , 7283
Abstract
The bioavailability of orally administered drugs could be impacted by intestinal and hepatic first-pass metabolism. Testosterone undecanoate (TU), an orally administered ester prodrug of testosterone, is significantly subjected to first-pass metabolism. However, the individual contribution of intestinal and hepatic first-pass metabolism is not well determined. Therefore, the aim of the current study was to predict the metabolic contribution of each site. The hydrolysis–time profiles of TU incubation in human liver microsomes and Caco-2 cell homogenate were used to predict hepatic and intestinal first-pass metabolism, respectively. The in vitro half-life (t1/2 inv) for the hydrolysis of TU in microsomal mixtures was 28.31 ± 3.51 min. By applying the “well-stirred” model, the fraction of TU that could escape hepatic first-pass metabolism (FH) was predicted as 0.915 ± 0.009. The incubation of TU in Caco-2 cell homogenate yielded t1/2 inv of 109.28 ± 21.42 min, which was applied in a “Q gut” model to estimate the fraction of TU that would escape intestinal first-pass metabolism (FG) as 0.114 ± 0.02. Accordingly, only 11% of the absorbed fraction of TU could escape intestinal metabolism, while 91% can pass through hepatic metabolism. Hence, compared to the liver, the intestinal wall is the main site where TU is significantly metabolised during first-pass effect.Keywords
This publication has 40 references indexed in Scilit:
- Dietary Fat Modulates the Testosterone Pharmacokinetics of a New Self‐Emulsifying Formulation of Oral Testosterone Undecanoate in Hypogonadal MenJournal of Andrology, 2012
- The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human DiseasesAdvances in Urology, 2011
- Chemical and Enzymatic Stability of Amino Acid Prodrugs Containing Methoxy, Ethoxy and Propylene Glycol LinkersMolecular Pharmaceutics, 2009
- In Silico Modeling of Nonspecific Binding to Human Liver MicrosomesDrug Metabolism and Disposition, 2008
- Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal IncubationsDrug Metabolism and Disposition, 2008
- Structure, function and regulation of carboxylesterasesChemico-Biological Interactions, 2006
- BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENTDrug Metabolism and Disposition, 2006
- EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCEDrug Metabolism and Disposition, 2004
- Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated DogsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- First-Pass EliminationClinical Pharmacokinetics, 1984